Company: REVB
Filing Date: 2025-05-23
Form Type: S-1/A
Source: 0001213900-25-047104
Chunk: 231

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-23
Form: S-1/A
Chunk 231
---
 Chief Executive
Officer. The CODM assesses the performance of the Company and decides how to allocate resources based upon consolidated net loss that
is also reported within the condensed consolidated statements of operations. The measure of segment assets that is reviewed by the CODM
is reported within the condensed consolidated balance sheets as consolidated total assets. The CODM uses consolidated net loss to monitor
period-over-period results and decides where to allocate and invest additional resources within the business to continue growth.

| Segment operating expenses:                             
 Research and development:                               |     | Three Months Ended 
 March 31,          
 2025               |            |   |     | 2024 |            |   |
|:--------------------------------------------------------|:----|:-------------------|-----------:|:--|:----|:-----|-----------:|:--|
| GEM-AKI, GEM-CKD and GEM-PSI clinical study expenses    |     | $                  |    470,578 |   |     | $    |    333,225 |   |
| Other expenses(1)                                       |     |                    |     23,613 |   |     |      |     89,015 |   |
| Personnel expenses (including stock-based compensation) |     |                    |    364,639 |   |     |      |    295,342 |   |
| General and administrative                              |     |                    |  1,236,157 |   |     |      |  1,184,556 |   |
| Change in fair value of warrant liability               |     |                    |     (1,417 | ) |     |      |    (68,427 | ) |
| Other income (expense), net(2)                          |     |                    |    (42,485 | ) |     |      |    847,722 |   |
| Net loss                                                |     | $                  | (2,051,085 | ) |     | $    | (2,681,433 | ) |

| (1) | Other research and development expenses primarily consist of facilities charges, third party consultant costs, costs related to other product candidates, and other unallocated costs.     |
| (2) | Clinical trial related settlement expenses with A-IR Clinical Research Ltd., foreign currency transaction gains and losses and interest income from our cash balances in savings accounts. |

F-41 REVELATION BIOSCIENCES, INC. Up to 1,949,317 Shares